A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies

The primary objective of the study for Cohort 1 and Cohort 2 is to assess the anticancer activity of emavusertib in combination with zanubrutinib in participants with CLL.

Trial Details

NCT ID
NCT07271667
Phase
PHASE2
Sponsor
Curis, Inc.
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Emavusertib
  • Zanubrutinib
Locations (sample)
  • Miami Beach, Florida, United States|25.79065,-80.13005
  • Rochester, Minnesota, United States|44.02163,-92.4699
  • Florham Park, New Jersey, United States|40.78788,-74.38821
  • Columbus, Ohio, United States|39.96118,-82.99879
  • Pittsburgh, Pennsylvania, United States|40.44062,-79.99589

Key Eligibility Criteria

  • Males and females ≥ 18 years of age.
  • Life expectancy of ≥ 3 months.
  • Eastern Cooperative Oncology Group Performance Status of 0, 1, or 2.
  • Histopathologically confirmed diagnosis of CLL (medical record is acceptable), as per the World Health Organization 2016 classification.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →